Literature DB >> 12001120

A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma.

Masato Hareyama1, Koh-ichi Sakata, Hiroki Shirato, Takeshi Nishioka, Masamichi Nishio, Keishiro Suzuki, Akio Saitoh, Atsushi Oouchi, Satoshi Fukuda, Tetsuo Himi.   

Abstract

BACKGROUND: A prospective, randomized study was performed to determine the efficacy of neoadjuvant chemotherapy over radiotherapy alone in patients with locally advanced nasopharyngeal carcinoma.
METHODS: From January 1991 to December 1998, 80 patients were enrolled in this study. Patients with locoregional carcinoma of the nasopharynx were randomized to receive two courses of chemotherapy, consisting of cisplatin and 5-fluorouracil (CDDP-5FU), that were administered before radiation therapy (CT arm) or radiotherapy alone. The patients who received neoadjuvant chemotherapy were treated with radiation therapy, which was scheduled to commence 2 weeks after the second course chemotherapy.
RESULTS: With a median follow-up of 49 months, a trend toward improved overall survival or disease free survival favoring the CT arm was observed (5-year overall survival rate, 60% vs. 48%; 5-year disease free survival rate, 55% vs. 43%), although this difference was not significant. There were no differences in locoregional failure free survival between the two arms. However, metastasis free survival favored the CT arm, although this difference was not significant. The results also demonstrated that most patients in the CT arm who experienced recurrent disease developed locoregional recurrences before distant metastases, suggesting that improvements in locoregional control may lead to improved disease free survival.
CONCLUSIONS: The use of CDDP-5FU chemotherapy prior to radiotherapy in patients with nasopharyngeal carcinoma did not result in a significant improvement in disease free survival or overall survival. However, there was a positive tendency in favor of the CT arm for distant metastasis free survival, although there was no improvement in the locoregional recurrence free survival rate. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001120     DOI: 10.1002/cncr.10473

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  54 in total

1.  Ifosfamide-based chemotherapy in locoregionally advanced nasopharyngeal cancer: evaluation of its role as neoadjuvant chemotherapy.

Authors:  Sarbani Ghosh-Laskar; Jai Prakash Agarwal; Pranshu Mohindra; Manju Sengar; Shilpa Vyas; V R Pai; Ashwini Budrukkar; Prathamesh Pai; Anil K D'Cruz; Ketayun Ardeshir Dinshaw
Journal:  Med Oncol       Date:  2008-12-02       Impact factor: 3.064

2.  A prospective study on therapeutic gain by concurrent chemoradiotherapy for stage II-IV a nasopharyngeal carcinoma.

Authors:  Mei Qi; Hu Guangyuan; Long Guoxian; Qiu Hong; Fu Qiang; Hu Guoqing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-02-19

3.  Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.

Authors:  Federico Rotolo; Jean-Pierre Pignon; Jean Bourhis; Sophie Marguet; Julie Leclercq; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Yoke Lim Soong; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Li Zhang; Edwin Pun Hui; Anne W M Lee; Pierre Blanchard; Stefan Michiels
Journal:  J Natl Cancer Inst       Date:  2017-04       Impact factor: 13.506

Review 4.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

5.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

6.  Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.

Authors:  Hao Peng; Lei Chen; Yuan Zhang; Wen-Fei Li; Yan-Ping Mao; Fan Zhang; Rui Guo; Li-Zhi Liu; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  Oncologist       Date:  2016-08-05

7.  Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment.

Authors:  Francesco Moretto; Monica Rampino; Fernando Munoz; Maria Grazia Ruo Redda; Alessia Reali; Vittoria Balcet; Serena Badellino; Cristina Piva; Marina Schena; Mario Airoldi; Oliviero Ostellino; Giancarlo Pecorari; Riccardo Ragona; Umberto Ricardi
Journal:  Radiol Med       Date:  2014-01-15       Impact factor: 3.469

Review 8.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

9.  Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned?

Authors:  Serra Kamer; Mustafa Esassolak; Deniz Yalman; Bulent Karabulut; Yasemin Bolukbasi; Barbaros Aydin
Journal:  Med Oncol       Date:  2007-08-11       Impact factor: 3.064

10.  The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma.

Authors:  Banu Ozturk; Suleyman Buyukberber; Muge Akmansu; Ugur Coskun; Deniz Yamac; Aytug Uner; Emel Yaman; Ramazan Yildiz; A Osman Kaya; Huseyin Bora; Diclehan Unsal; Yucel Pak; Mustafa Benekli
Journal:  Med Oncol       Date:  2007-12-15       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.